Lupin Earns Prestigious S&P Global ESG Score of 91, Redefining Sustainability Leadership in Pharma
Mumbai, November 13, 2025: Lupin Limited (Lupin), a globally recognized pharmaceutical company, today announced that it has achieved an S&P Global ESG Score of 91 for 2025, dramatically outperforming the industry average of 28. With this milestone, Lupin joins a rare group of global enterprises that have crossed the 90-point benchmark.*
The transformation from a score of 17 in 2021 represents one of the most rapid ESG improvements within the pharmaceutical sector, highlighting Lupin’s unwavering focus on sustainable progress.
Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, commented, “Securing a score above 90 in the S&P Global ESG ratings is a significant global distinction that demonstrates our strong commitment to sustainability. With a 15-point rise from last year, Lupin not only leads the pharmaceutical industry but also establishes new standards for accountable growth. Our purpose-driven strategy ensures we continue to deliver healthcare innovations that create meaningful and lasting value for patients, communities, and stakeholders around the globe.”
The company has advanced across all three ESG dimensions. Environmentally, Lupin has scaled up renewable energy integration, reduced its carbon footprint, and achieved water-positive operations. Social initiatives have focused on employee well-being, diversity and inclusion, and impactful community health programs. From a governance standpoint, Lupin has strengthened transparency, reinforced ethical conduct, enhanced corporate governance mechanisms, and introduced board-level oversight to manage ESG risks and opportunities effectively.
About Lupin
Lupin Limited is a Mumbai-based global pharmaceutical company serving more than 100 markets. Its portfolio encompasses branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a strong presence in India and the United States across key therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin operates 15 advanced manufacturing facilities and 7 research centers globally and employs over 24,000 professionals. Through subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, Lupin remains committed to advancing patient health worldwide.
